EvolVeritas to develop antiviral drug against coronavirus
EvolVeritas said on Friday that it is developing an antiviral drug candidate against coronavirus with a HUF 220 million grant from Hungary's National Research, Development and Innovation Office (NKFIH), according to a report by state news wire MTI.
The company said it specializes in the development of protein-based drugs based on controlled evolution.
EvolVeritas also pledged to develop a new anti-thrombotic drug candidate that it had already begun working on before the coronavirus pandemic.
The planned deadline for the completion of the project is March 2022.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.